BLTE Belite Bio announces oral presentation at the asrs annual meeting featuring additional positive secondary endpoint data from the phase

BLTE Belite Bio announces oral presentation at the asrs annual meeting featuring additional positive secondary endpoint data from the phase 3 trial of tinlarebant in stargardt disease type 1 Belite Bio - tinlarebant well tolerated in phase 3 Dragon trial